Endostatin promising treatments for AIDS-related cancer

August 12, 2003

COLUMBUS, Ohio - New research suggests that the anti-tumor compound endostatin delivers a one-two punch to Kaposi's sarcoma - the most common AIDS-related cancer.

Endostatin seems to strike Kaposi's sarcoma (KS) lesions by preventing existing tumors from growing new blood vessels and also by stopping KS tumor cells from migrating through the body, said Susan Mallery, the study's lead author and a professor in the department of oral and maxillofacial surgery and pathology at Ohio State University's College of Dentistry.

A hallmark of the advanced stages of AIDS in many cases, KS lesions often appear as purplish growths on the palate and at various places on the skin. Mallery and her colleagues treated KS cells - taken from malignant lesions on AIDS patients - with endostatin.

Kaposi's sarcoma is similar to most other cancers in that it relies on the growth and formation of blood vessels in order to thrive. But KS is unique in that its cells both produce and respond to substances called growth factors - something not seen in most other types of cancer. This ability gives KS tumors an extra advantage in establishing new tumors throughout the body.

"It also makes KS an incredibly aggressive disease," Mallery said. But treating KS cells with endostatin in the laboratory seemed to stop the cells in their tracks - the cells had lost their ability to migrate and invade in response to growth factors.

While the laboratory results of the current study are promising, endostatin has proved a challenge in treatment.

"Human clinical trials in which endostatin was administered intravenously haven't been highly successful, but subsequent studies on animals where the subjects were treated with steady, local levels of endostatin have shown promise," she said. "A controlled, sustained and local release of endostatin might be a good approach when treating human patients with KS."

The study appears in a recent issue of the Journal of Cellular Biochemistry.

The researchers isolated KS cells from biopsy-confirmed tumors on AIDS patients and treated the cells with endostatin. Patients providing the cells had either failed medication therapy or hadn't received treatment. Groups of cells were treated with endostatin for specific lengths of time, ranging from 5 to 150 minutes - treating cells in such a fashion gave researchers an idea of how long it would take for endostatin to affect the cells.

Within a half an hour, endostatin had noticeably altered the shape of the KS cells - the cells had flattened out and had lost their characteristic spindle form. Previous studies have shown that endostatin quickly binds to and inhibits the filaments that are necessary for cell movement.

After an hour and a half, endostatin had infiltrated the cells' nuclei, where it altered the process of transcription - a mechanism by which a cell's genetic material reproduces. After nearly two hours, endostatin had cleared out of the cells, supporting the idea that a continuous, controlled-release of endostatin in the tumor area is a viable treatment option, Mallery said.

"KS cells are phagocytic - they eat things," she said. "Therefore, endostatin uptake by KS cells is rapid, after which the KS cells fail to mobilize the filaments needed for movement. If we could stop this KS cell migration in a human patient, then we could prevent a tumor from progressing beyond a small lesion."

Homosexual and bisexual men run the greatest risk for developing KS -- women rarely develop the disease.

In AIDS patients, KS is caused by human herpesvirus-8 (HHV-8), a sexually transmitted virus and one of the few established cancer-causing viruses. HHV-8 infects B-cells, immune system cells that produce inflammation-causing cytokines. This production of cytokines triggers an increased production of primitive cells called endothelial progenitor cells - cells that help repair damaged blood vessels. But in the case of HIV-positive people, this rampant production of endothelial cells can give rise to KS tumors.

Mallery believes that endostatin may stop these endothelial progenitor cells from proliferating. Endostatin is a potent angiostatic drug - in addition to preventing blood vessels from forming, it also stops new tumors from developing. In the case of KS, endostatin appears to cut the communication between the tumor cells and two key growth factors - VEGF and bFGF - both important to the formation of new blood vessels and in the development of new tumors.

It's thought that these growth factors help KS cells invade different parts of the body - that's why lesions can show up in random places.

"That makes a tremendous amount of sense in Kaposi's sarcoma, because the disease typically appears as numerous lesions on the body," Mallery said. "That's unusual for most cancers, which generally start with an isolated tumor and then spread."

Kaposi's sarcoma is far less common today than it was in the 1980s and the early 1990s. Back then, it was an early sign of full-blown AIDS infection. Subsequent developments of effective anti-HIV treatments, such as the potent highly active anti-retroviral therapy (HAART), significantly decreased the number of AIDS patients that developed KS.

"We're not seeing nearly the amount of KS that we saw a decade or more ago - it's become more of an end-stage disease," Mallery said. "The people developing KS now are typically those who have failed HAART."

Mallery said the next step is to look into using biodegradable polymer particles to provide a controlled, sustained release of endostatin over the span of several months.

"Endostatin is a good drug, but the problem is that treating a patient intravenously with endostatin won't yield a therapeutic concentration at the tumor site," she said.

"Treating KS lesions locally could be particularly helpful for patients in whom the disease is limited to the skin and mucus membranes," Mallery continued. "Based on what we saw in the laboratory, the cells wouldn't be able to make another tumor after treatment with endostatin, and the existing tumor would likely regress."

Support for this research came from the National Institutes of Health/National Institute of Dental and Craniofacial Research and the National Cancer Institute.

Mallery conducted the study with David Schuller, Director of the James Cancer Hospital and Solove Research Institute at Ohio State; Ralph Wilson, Ping Pei, Gregory Ness, Jennifer Bradburn and Robert Renner, all with the departments of oral maxillofacial surgery and pathology and periodontoloty at Ohio State's College of Dentistry; Mark Morse, with Ohio State's School of Public Health and Ohio State's Comprehensive Cancer Center; and Fredika Robertson, of the department of molecular virology, immunology and medical genetics at Ohio State.
-end-
Contact: Susan Mallery, (614) 292 5892; Mallery.1@osu.edu
Written by Holly Wagner, (614) 292-8310; Wagner.235@osu.edu

Ohio State University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.